153 related articles for article (PubMed ID: 11498515)
21. The nonpeptide B2 receptor antagonist FR173657: inhibition of effects of bradykinin related to its role in nociception.
Griesbacher T; Amann R; Sametz W; Diethart S; Juan H
Br J Pharmacol; 1998 Jul; 124(6):1328-34. PubMed ID: 9720808
[TBL] [Abstract][Full Text] [Related]
22. S 16118 (p-guanidobenzoyl-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) is a potent and long-acting bradykinin B2 receptor antagonist, in vitro and in vivo.
Félétou M; Robineau P; Lonchampt M; Bonnardel E; Thurieau C; Fauchère JL; Widdowson P; Mahieu JP; Serkiz B; Volland JP
J Pharmacol Exp Ther; 1995 Jun; 273(3):1071-7. PubMed ID: 7791077
[TBL] [Abstract][Full Text] [Related]
23. Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657).
Gobeil F; Montagne M; Inamura N; Regoli D
Immunopharmacology; 1999 Sep; 43(2-3):179-85. PubMed ID: 10596851
[TBL] [Abstract][Full Text] [Related]
24. Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice.
Corrêa CR; Kyle DJ; Chakraverty S; Calixto JB
Br J Pharmacol; 1996 Feb; 117(3):552-558. PubMed ID: 8821548
[TBL] [Abstract][Full Text] [Related]
25. Effects of the bradykinin B2 receptor antagonist S 16118 (p-guanidobenzoyl-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) in different in vivo animal models of inflammation.
Félétou M; Lonchampt M; Robineau P; Jamonneau I; Thurieau C; Fauchère JL; Villa P; Ghezzi P; Prost JF; Canet E
J Pharmacol Exp Ther; 1995 Jun; 273(3):1078-84. PubMed ID: 7791078
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo effects of kinin B(1) and B(2) receptor agonists and antagonists in inbred control and cardiomyopathic hamsters.
Hallé S; Gobeil F; Ouellette J; Lambert C; Regoli D
Br J Pharmacol; 2000 Apr; 129(8):1641-8. PubMed ID: 10780969
[TBL] [Abstract][Full Text] [Related]
27. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor.
Ishihara K; Kamata M; Hayashi I; Yamashina S; Majima M
Int Immunopharmacol; 2002 Mar; 2(4):499-509. PubMed ID: 11962729
[TBL] [Abstract][Full Text] [Related]
28. Bradykinin B2 and GPR100 receptors: a paradigm for receptor signal transduction pharmacology.
Meini S; Bellucci F; Cucchi P; Giuliani S; Quartara L; Giolitti A; Zappitelli S; Rotondaro L; Boels K; Maggi CA
Br J Pharmacol; 2004 Dec; 143(8):938-41. PubMed ID: 15545289
[TBL] [Abstract][Full Text] [Related]
29. Anion secretory effects of a non-peptide mimic of bradykinin (FR190997) on mouse colon epithelium.
Cuthbert AW
Immunopharmacology; 1999 Dec; 45(1-3):191-8. PubMed ID: 10615011
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of the vascular response to kinins by inhibition of myocardial kininases.
Dendorfer A; Wolfrum S; Schäfer U; Stewart JM; Inamura N; Dominiak P
Hypertension; 2000 Jan; 35(1 Pt 1):32-7. PubMed ID: 10642271
[TBL] [Abstract][Full Text] [Related]
31. A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor: evidence from mutational analysis.
Bellucci F; Meini S; Cucchi P; Catalani C; Reichert W; Zappitelli S; Rotondaro L; Quartara L; Giolitti A; Maggi CA
Br J Pharmacol; 2003 Oct; 140(3):500-6. PubMed ID: 12970081
[TBL] [Abstract][Full Text] [Related]
32. Bradykinin down-regulates LPS-induced eosinophil accumulation in the pleural cavity of mice through type 2-kinin receptor activation: a role for prostaglandins.
Silva AR; Larangeira AP; Pacheco P; Calixto JB; Henriques MG; Bozza PT; Castro-Faria-Neto HC
Br J Pharmacol; 1999 May; 127(2):569-75. PubMed ID: 10385260
[TBL] [Abstract][Full Text] [Related]
33. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Aramori I; Hatori C; Sawai H; Oku T; Tanaka H
J Med Chem; 1998 Oct; 41(21):4062-79. PubMed ID: 9767643
[TBL] [Abstract][Full Text] [Related]
34. Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects.
deBlois D; Horlick RA
Br J Pharmacol; 2001 Jan; 132(1):327-35. PubMed ID: 11156593
[TBL] [Abstract][Full Text] [Related]
35. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Aramori I; Hatori C; Sawai H; Oku T; Tanaka H
J Med Chem; 1998 Nov; 41(23):4587-98. PubMed ID: 9804698
[TBL] [Abstract][Full Text] [Related]
36. Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists.
Hayashi I; Majima M
Br J Pharmacol; 1999 Jan; 126(1):197-204. PubMed ID: 10051136
[TBL] [Abstract][Full Text] [Related]
37. Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammation.
Asano M; Hatori C; Inamura N; Sawai H; Hirosumi J; Fujiwara T; Nakahara K
Br J Pharmacol; 1997 Dec; 122(7):1436-40. PubMed ID: 9421292
[TBL] [Abstract][Full Text] [Related]
38. Changes in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized rats.
Damas J; Hallet C; Lefebvre PJ
Br J Pharmacol; 2001 Nov; 134(6):1312-8. PubMed ID: 11704652
[TBL] [Abstract][Full Text] [Related]
39. Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors.
Hirate K; Uchida A; Ogawa Y; Arai T; Yoda K
Neurosci Res; 2006 Apr; 54(4):288-94. PubMed ID: 16473424
[TBL] [Abstract][Full Text] [Related]
40. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Hatori C; Sawai H; Oku T; Tanaka H
J Med Chem; 1998 Oct; 41(21):4053-61. PubMed ID: 9767642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
